STOCK TITAN
  1. Home
  2. Sec-filings
  3. JNJ
  4. [Form 4] Johnson & Johnson Insider Trading Activity

[Form 4] Johnson & Johnson Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock JNJ logo
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

#25 Ranked by Market Cap
#1040 Ranked by Dividends

JNJ Latest News

Jul 17, 2025
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
Jul 16, 2025
Dean Omar Branham Shirley Attorney Named Among Nation’s Top Future Legal Leaders
Jul 16, 2025
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025
Jul 16, 2025
Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook
Jul 8, 2025
Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

JNJ Latest SEC Filings

Jul 17, 2025
[144] Johnson & Johnson SEC Filing
Jul 16, 2025
[8-K] Johnson & Johnson Reports Material Event
Jul 8, 2025
[Form 3] Johnson & Johnson Initial Statement of Beneficial Ownership

JNJ Stock Data

379.41B
2.40B
0.06%
73.56%
0.96%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK